2003
DOI: 10.1016/s1064-7406(03)00090-7
|View full text |Cite
|
Sign up to set email alerts
|

Relevant anatomy for botulinum toxin facial rejuvenation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2006
2006
2023
2023

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(12 citation statements)
references
References 8 publications
0
12
0
Order By: Relevance
“…12 The addition of these 2 sites targeting the frontalis muscle did not increase the efficacy. However, only wrinkles in the glabellar area were evaluated in this trial, and we cannot rule out the possibility that evaluation of central forehead wrinkles would have shown the 5-injection site pattern to be more effective.…”
Section: Commentmentioning
confidence: 95%
“…12 The addition of these 2 sites targeting the frontalis muscle did not increase the efficacy. However, only wrinkles in the glabellar area were evaluated in this trial, and we cannot rule out the possibility that evaluation of central forehead wrinkles would have shown the 5-injection site pattern to be more effective.…”
Section: Commentmentioning
confidence: 95%
“…Thus, treatment formulas that are universal are wasteful and unnecessary. 7,9,10,13,14 The corrugator supercilii and depressor orbicularis oculi muscles are clinically indistinguishable, and their anatomy is poorly understood. In the vast majority of patients, the corrugator follows the course of the eyebrow and delicately interdigitates with the orbicularis oculi muscle laterally and frontalis muscle superiorly, which contrasts with schematic diagrams showing the tail (insertion) of the corrugator 1 cm above the brow.…”
Section: Neuromodulator Applicationsmentioning
confidence: 99%
“…When injecting below the eye, a snap test must be performed prior to treatment to avoid the potential for corneal show following treatment (8)(9)(10)12). Often in these expanded applications, the agonist muscle is treated, allowing the antagonist muscle to exhibit overactivity.…”
Section: Botulinum Neurotoxin Type a In The Upper Facementioning
confidence: 99%